Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

46.85USD
17 May 2019
Change (% chg)

$-0.27 (-0.57%)
Prev Close
$47.12
Open
$46.69
Day's High
$47.23
Day's Low
$46.59
Volume
2,502,914
Avg. Vol
4,892,842
52-wk High
$63.69
52-wk Low
$44.30

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Co Says CEO Giovanni Caforio's 2018 Total Compensation Was $19.4 Mln Vs $18.7 Mln In 2017
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CO - CEO GIOVANNI CAFORIO'S 2018 TOTAL COMPENSATION WAS $19.4 MILLION VERSUS $18.7 MILLION IN 2017 - SEC FILING.BRISTOL-MYERS SQUIBB CO - CFO CHARLES BANCROFT'S 2018 TOTAL COMPENSATION WAS $7.9 MILLION VERSUS $8.8 MILLION IN 2017 - SEC FILING.BRISTOL-MYERS SQUIBB CO - CEO CAFORIO'S 2018 TOTAL COMPENSATION WAS 173 TIMES MORE THAN THAT OF MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES.  Full Article

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb
Friday, 12 Apr 2019 

April 12 (Reuters) - Celgene Corp ::CELGENE STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY BRISTOL-MYERS SQUIBB.CELGENE CORP - CELGENE EXPECTS TRANSACTION TO CLOSE IN Q3 OF 2019.CELGENE CORP - APPROXIMATELY 98% OF VOTES CAST, AND OVER 70% OF SHARES OUTSTANDING AND ENTITLED TO VOTE, VOTED IN FAVOR OF TRANSACTION.  Full Article

Bristol-Myers Says It Is Pleased Celgene Reached Settlement With Alvogen On Revlimid Patent Litigation
Friday, 29 Mar 2019 

March 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON CELGENE’S SETTLEMENT WITH ALVOGEN ON REVLIMID® PATENT LITIGATION.BRISTOL-MYERS SQUIBB CO - CONFIDENT IN STRENGTH OF OUR COMBINATION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - CO, CELGENE EXPECT TRANSACTION TO CLOSE IN Q3.BRISTOL-MYERS SQUIBB CO - PLEASED THAT CELGENE HAS REACHED A SETTLEMENT WITH ALVOGEN RELATED TO PATENTS FOR REVLIMID.  Full Article

Starboard To Withdraw Proxy Solicitation to Vote Against Bristol-Myers & Celgene Deal
Friday, 29 Mar 2019 

March 29 (Reuters) - Starboard Value LP::STARBOARD ISSUES STATEMENT ON BRISTOL-MYERS.HAS DECIDED TO WITHDRAW ITS PROXY SOLICITATION TO VOTE AGAINST CELGENE TRANSACTION."CONTINUE TO FEEL STRONGLY THAT PROPOSED TRANSACTION BETWEEN BRISTOL-MYERS AND CELGENE CORPORATION IS A BAD DEAL FOR SHAREHOLDERS".CONTINUE TO INTEND TO VOTE SHARES AGAINST BRISTOL-MYERS AND CELGENE DEAL AT UPCOMING SPECIAL MEETING.  Full Article

Bristol-Myers Squibb And Concerto HealthAI Announce Strategic Agreement
Thursday, 28 Mar 2019 

March 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND CONCERTO HEALTHAI ANNOUNCE STRATEGIC AGREEMENT.BRISTOL-MYERS SQUIBB - MULTI-YEAR STRATEGIC AGREEMENT WITH CONCERTO HEALTHAI WILL COVER A DIVERSE RANGE OF CANCERS, INTEGRATE MULTIPLE DATA SOURCES.BRISTOL-MYERS SQUIBB CO - WILL USE CONCERTO HEALTHAI'S PLATFORM, EUREKAHEALTH, TO ACCELERATE INSIGHTS.  Full Article

Starboard Opposes Bristol-Myers' Proposed Acquisition Of Celgene
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Bristol-Myers Squibb Co ::STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD VALUE SAYS BELIEVES PROPOSED MERGER WITH CELGENE IS NOT IN BEST INTERESTS OF BRISTOL-MYERS SHAREHOLDERS.STARBOARD VALUE SAYS URGES ALL BRISTOL-MYERS SHAREHOLDERS TO REJECT PROPOSED CELGENE TRANSACTION.STARBOARD VALUE SAYS MAILED DEFINITIVE PROXY MATERIALS AND A BLUE PROXY CARD IN CONNECTION WITH BRISTOL-MYERS SQUIBB SPECIAL MEETING OF SHAREHOLDERS.  Full Article

Starboard Now Owns 4.4 Mln Bristol-Myers Shares-Filing
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::ACTIVIST HEDGE FUND STARBOARD SAYS NOW OWNS 4.4 MILLION BRISTOL-MYERS SHARES-FILING.  Full Article

Bristol-Myers Squibb Says Celgene Deal Is The Best Path Forward
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB 27, SAYS "WE ARE VERY DISAPPOINTED BY POSITION OF WELLINGTON MANAGEMENT".BRISTOL-MYERS SQUIBB, IN LETTER TO EMPLOYEES ON FEB. 27, SAYS "BELIEVE THAT THE CELGENE TRANSACTION IS THE BEST PATH FORWARD FOR OUR COMPANY".  Full Article

Bristol-Myers Squibb Co - Employee Workforce Reductions Were About 900 In 2018, 1,900 In 2017 And 1,100 In 2016
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB CO - EMPLOYEE WORKFORCE REDUCTIONS WERE ABOUT 900 IN 2018, 1,900 IN 2017 AND 1,100 IN 2016.  Full Article

EU Medicines Agency Recommends Approval Of Pfizer's Vizimpro, Bristol-Myers' Reyataz
Friday, 1 Feb 2019 

Feb 1 (Reuters) - EMA's CHMP::EU MEDICINES AGENCY RECOMMENDATIONS FOR JAN 2019.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER’S LUNG CANCER DRUG VIZIMPRO.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF BRISTOL-MYERS SQUIBB’S HIV DRUG REYATAZ.  Full Article

Bristol-Myers' Opdivo fails late-stage brain cancer trial

May 9 Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.